The estimated Net Worth of Owen N. Witte is at least $7.36 Million dollars as of 11 August 2022. Owen Witte owns over 15,000 units of Allogene Therapeutics Inc stock worth over $635,169 and over the last 8 years he sold ALLO stock worth over $6,247,223. In addition, he makes $474,988 as Independent Director at Allogene Therapeutics Inc.
Owen has made over 9 trades of the Allogene Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of ALLO stock worth $251,250 on 11 August 2022.
The largest trade he's ever made was selling 25,000 units of Allogene Therapeutics Inc stock on 23 June 2017 worth over $2,507,500. On average, Owen trades about 6,840 units every 99 days since 2017. As of 11 August 2022 he still owns at least 218,271 units of Allogene Therapeutics Inc stock.
You can see the complete history of Owen Witte stock trades at the bottom of the page.
Dr. Owen N. Witte, M.D. serves as Independent Director of the Company. Dr. Witte previously served as a member of the board of directors of Kite Pharma, Inc. (“Kite”) from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President’s Cancer Panel. Dr. Witte holds a bachelor’s degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology.
As the Independent Director of Allogene Therapeutics Inc, the total compensation of Owen Witte at Allogene Therapeutics Inc is $474,988. There are 16 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Owen Witte is 70, he's been the Independent Director of Allogene Therapeutics Inc since 2018. There are 4 older and 16 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun, and Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: